J. Hager

发表

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

S. Larson, M. Gönen, M. Morris, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas

Joe W. Gray, Graeme Hodgson, Daniel Pinkel, 2001, Nature Genetics.

XIAP is not required for human tumor cell survival in the absence of an exogenous death signal

R. Peach, J. Sensintaffar, J. Hager, 2010, BMC Cancer.

Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2015, Bioorganic & medicinal chemistry letters.

Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model.

S. Geller, A. Pollard, F. Jirik, 1988, Science.

Tumor Cells Utilize Multiple Pathways to Down‐modulate Apoptosis: Lessons from a Mouse Model of Islet Cell Carcinogenesis

D. Hanahan, J. Hager, 1999, Annals of the New York Academy of Sciences.

Hormone-Targeted Therapy and Resistance

L. Friedman, J. Hager, C. Metcalfe, 2018 .

Development of antiandrogen ARN-509 1 ARN-509 : a novel antiandrogen for prostate cancer treatment

E. Stanchina, H. Scher, V. Arora, 2012 .

Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2019, Bioorganic & medicinal chemistry letters.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling

C. Hassig, J. Hager, M. Mapara, 2008, Molecular Cancer Therapeutics.

Induction of female Sex-lethal RNA splicing in male germ cells: implications for Drosophila germline sex determination.

T. Cline, J. Hager, Jeffrey H. Hager, 1997, Development.

Development of anti-androgen ARN-509 1 ARN-509: a novel anti-androgen for prostate cancer treatment

H. Scher, V. Arora, C. Sawyers, 2012 .

Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis

D. Hanahan, J. Hager, O. Casanovas, 2005, Oncogene.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

A. Saven, T. Rao, J. Malecha, 2008, Molecular Cancer Therapeutics.

Alpha-mercaptoketone based histone deacetylase inhibitors.

J. Malecha, T. Z. Hoffman, B. Wiley, 2008, Bioorganic & medicinal chemistry letters.

Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.

T. Rao, J. Malecha, T. Z. Hoffman, 2008, Bioorganic & medicinal chemistry letters.

Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas

D. Hanahan, D. Pinkel, D. Albertson, 2001, Nature Genetics.

ARN-509: a novel antiandrogen for prostate cancer treatment.

H. Scher, V. Arora, C. Sawyers, 2012, Cancer research.

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Mamie Yu, A. Daemen, R. Houtman, 2019, Cell.

Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis.

D. Hanahan, M. Bogyo, E. Giraudo, 2004, Cancer cell.

Genetic Ablation of Bcl-x Attenuates Invasiveness without Affecting Apoptosis or Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Cancer

D. Hanahan, L. Hennighausen, J. Hager, 2009, PloS one.

Oncogene Expression and Genetic Background Influence the Frequency of DNA Copy Number Abnormalities in Mouse Pancreatic Islet Cell Carcinomas

D. Hanahan, J. Fridlyand, J. Gray, 2004, Cancer Research.

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

Gang Shao, B. Darimont, J. Sensintaffar, 2013, Cancer discovery.

Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite Instability

L. Kategaya, J. Hager, Senthil K. Perumal, 2019, iScience.

Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas

D. Hanahan, D. Pinkel, J. Gray, 2001, Nature Genetics.

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

K. Walter, Andiliy G. Lai, J. Giltnane, 2016, eLife.

Of Mice and MEN1: Insulinomas in a Conditional Mouse Knockout

D. Hanahan, F. Collins, T. Ried, 2003, Molecular and Cellular Biology.

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2015, Journal of medicinal chemistry.

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis.

D. Hanahan, M. Inoue, N. Ferrara, 2002, Cancer cell.

KD 5170 , a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

A. Saven, T. Rao, J. Malecha, 2008 .

Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2018, ACS medicinal chemistry letters.

Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2018, Journal of medicinal chemistry.

Abstract 1943: PARG inhibitors exhibit synthetic lethality with XRCC1 deficiency and a cellular mechanism of action that is distinct from PARP inhibition

Kedar S Vaidya, M. P. Dillon, M. Fischer, 2018, Experimental and Molecular Therapeutics.

Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer

E. Winer, J. Baselga, A. Bardia, 2015 .

Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927

Jun Liang, A. Daemen, Andiliy G. Lai, 2018, Cancer Chemistry.

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Mamie Yu, A. Daemen, R. Houtman, 2019, Cell.

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2015, Journal of medicinal chemistry.